Delivery Order SPE2DB24D2106-SPE2DB24FAUMT

Award Date 7/15/24
Potential Completion Date 7/16/24
Potential Value $2.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The contract has a ceiling value of $2,371.46 and a final completion date of July 31, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,366.07 contract is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a performance period ending on May 20, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the agency to issue delivery orders for a...
This is a $1,903.48 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized medication, to support the medical supply needs of military healthcare facilities. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract is for the delivery of a pharmaceutical product, Quillivant XR 25 mg/5 ml suspension, with a ceiling value of $2,076.13. The contract has a firm fixed-price pricing type and is a delivery order with an ultimate completion date of April 5, 2024. This award appears to be part of a larger indefinite delivery contract (IDV) that DMS...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The $5,393.20 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) under the SPE2DB24 indefinite delivery contract, which has a ceiling value of up to $499,999,999 and runs through December 31, 2025. This single-award IDC allows the DLA to issue delivery orders for a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension, 120 ml, with a ceiling value of $3,379.20 and a completion date of June 11, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $1,314.20, is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) and has a period of performance through May 13, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the agency to issue...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,440.48 contract is for the delivery of Quillivant XR 25 mg/5 ml suspension in a 150 ml bottle. The contract has an ultimate completion date of March 3, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract...
This federal contract award issued by the Defense Logistics Agency (DLA) is a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,537.17 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized prescription medication. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles, with a ceiling value of $2,412.14 and a completion date of July 3, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler based in Park Ridge, Illinois that specializes in providing a range of pharmaceutical products to federal...
  • SPE2DB24D2106
    Indefinite Delivery Contract
  • SPE2DB24D2106-SPE2DB24FAUMT
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of Quillivant XR 25 mg/5 ml suspension (120 ml) and has a ceiling value of $2,280.55. The contract has a period of performance through July 16, 2024.

The contract is issued under the DLA's SPE2DB pharmaceutical prime vendor program, a single-award indefinite delivery contract (IDC) valued up to $499,999,999 that allows the DLA to order a comprehensive range of pharmaceutical items to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group holds this major IDC with the DLA, through which it provides a vast array of medications, including both common and specialized pharmaceutical products, to DoD healthcare facilities.

This delivery order does not have a set-aside designation. DMS Pharmaceutical Group, a woman-owned small business, has been able to secure direct awards for pharmaceutical prime vendor programs supporting military medical facilities globally through its small business status.

Generated 10/14/24, 10:05 AM